0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > FOLR1

FOLR1

Brief Information

Name:Folate receptor alpha
Target Synonym:FRalpha,KB cells FBP,Adult folate-binding protein,Folate receptor 1,Folate receptor alpha,FR-alpha,FOLR1,Ovarian Tumor-Associated Antigen MOv18,Folate Receptor 1 (Adult),Folate Receptor, Adult,FOLR,FBP,Folate Binding Protein,FRα
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:10
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

Part of Bioactivity data

FO1-HF2H8-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

2e5 of Anti-FOLR1 CAR-293 cells were stained with 100 μL of 3 μg/mL of FITC-Labeled Human FOLR1, His Tag (Cat. No. FO1-HF2H8) and negative control protein respectively, FITC signals was used to evaluate the binding activity (QC tested).

FO1-H52H1-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

2e5 of Anti-FOLR1 CAR-293 cells were stained with 100 μL of 0.3 μg/mL of Human FOLR1, His Tag (Cat. No. FO1-H52H1) and negative control protein respectively, washed and then followed by PE anti-His antibody and analyzed with FACS (Routinely tested).

FO1-H52H1-ELISA
Human FOLR1, His TagHuman FOLR1, His Tag (Cat. No. FO1-H52H1) ELISA bioactivity

Immobilized Folic Acid-BSA Conjugate at 5 μg/mL (100 μL/well) can bind Human FOLR1, His Tag (Cat. No. FO1-H52H1) with a linear range of 5-78 ng/mL (QC tested).

FO1-HF2H8-MALS-HPLC
FITC-Labeled Human FOLR1, His Tag (Cat. No. ) MALS images

The purity of FITC-Labeled Human FOLR1, His Tag (Cat. No. FO1-HF2H8) was more than 90% and the molecular weight of this protein is around 40-50 kDa verified by SEC-MALS.

Bioactivity-ELISA
FITC-Labeled Human FOLR1, His TagFITC-Labeled Human FOLR1, His Tag (Cat. No. FO1-HF2H8) ELISA bioactivity

Immobilized Folic acid-BSA conjugate at 5 μg/mL (100 μL/well) can bind FITC-Labeled Human FOLR1, His Tag (Cat. No. FO1-HF2H8) with a linear range of 0.078-1.25 μg/mL (QC tested).

Synonym Name

FOLR-1,FBP,FOLR

Background

Folate Receptor 1 (FOLR1) is also known as Folate receptor alpha, Folate Binding Protein (FBP), FOLR, and is a member of the folate receptor (FOLR) family. Members of this gene family have a high affinity for folic acid and for several reduced folic acid derivatives, and mediate delivery of 5-methyltetrahydrofolate to the interior of cells. Mature FOLR1 is an N-glycosylated protein that is anchored to the cell surface by a GPI linkage. FOLR1 is predominantly expressed on epithelial cells and is dramatically upregulated on many carcinomas. FOLR1 is internalized to the endosomal system where it dissociates from its ligand before recycling to the cell surface. A soluble form of FOLR1 can be proteolytically shed from the cell surface into the serum and breast milk. Defects in FOLR1 are the cause of neurodegeneration due to cerebral folate transport deficiency (NCFTD). NCFTD is an autosomal recessive disorder resulting from brain-specific folate deficiency early in life.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
MORAb-202 MORAb-202 Phase 2 Clinical Eisai Co Ltd, Morphotek Neoplasms Details
EC-1456 EC-1456; EC-0531 Phase 1 Clinical Novartis Pharma Ag Ovarian Neoplasms; Carcinoma, Non-Small-Cell Lung Details
GALE-302 E-39; J-65; GALE-302 Phase 2 Clinical Galena Biopharma Ovarian Neoplasms; Breast Neoplasms Details
Noscapine-folate conjugate Phase 1 Clinical Emory University Hematologic Neoplasms; Inflammation Details
Vintafolide EC-145; MK-8109 Phase 2 Clinical Novartis Pharma Ag Ovarian Neoplasms; Solid tumours; Adenocarcinoma of Lung; Breast Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung Details
STRO-002 SP-7219; SP-7675; SP-7676; STRO-002; DBCO-Alexa647-conjugated SP7219 Phase 1 Clinical Sutro Biopharma Ovarian Neoplasms; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Endometrioid Details
Farletuzumab MORAb-003 Phase 3 Clinical Morphotek Ovarian Neoplasms; Solid tumours; Adenocarcinoma of Lung; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Fallopian Tube Neoplasms Details
OTL-38 EC-17; OTL-38; OTL-0038; Pteroyl-L-Tyr-S0456 Phase 3 Clinical On Target Ovarian Neoplasms; Carcinoma, Renal Cell; Lung Neoplasms Details
MOv18 IgE (King's College London) Phase 1 Clinical King'S College London, Cancer Research Uk Neoplasms Details
Mirvetuximab soravtansine IMGN-853; M9346-Asulfo-SPDB-DM4 Phase 3 Clinical Immunogen Inc Ovarian Neoplasms; Solid tumours; Carcinoma, Ovarian Epithelial; Breast Neoplasms; Peritoneal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms Details

This web search service is supported by Google Inc.

totop